Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combinations of protein farnesyltransferase and HMG CoA reductase inhibitors and their use to treat cancer

Combinations of protein farnesyltransferase and HMG CoA reductase inhibitors and their use to treat cancer

US Patent 6492410 · Granted Dec 10, 2002

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivati2025
Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and me2023
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivati2023
Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors2023
Small molecule inhibitors of EGFR and PI3K2023
Fixed dose combinations and formulations comprising ETC1002 and one or more stat2021
Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and me2021
Small molecule inhibitors of EGFR and PI3K2020
Small molecule inhibitors of EGFR and PI3K2019
Apolipoprotein mixtures2017
Statin-carboxyalkylether combinations2013
Fourier transform mass spectrometry of complex biological samples2005